JP2016512562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512562A5 JP2016512562A5 JP2016501962A JP2016501962A JP2016512562A5 JP 2016512562 A5 JP2016512562 A5 JP 2016512562A5 JP 2016501962 A JP2016501962 A JP 2016501962A JP 2016501962 A JP2016501962 A JP 2016501962A JP 2016512562 A5 JP2016512562 A5 JP 2016512562A5
- Authority
- JP
- Japan
- Prior art keywords
- oil
- api
- pharmaceutical composition
- eye
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004530 micro-emulsion Substances 0.000 claims description 91
- 239000004094 surface-active agent Substances 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 81
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 239000003921 oil Substances 0.000 claims description 59
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 51
- 229920000136 polysorbate Polymers 0.000 claims description 49
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 44
- 239000003937 drug carrier Substances 0.000 claims description 44
- 229960002297 fenofibrate Drugs 0.000 claims description 44
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 44
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 39
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 229950008882 polysorbate Drugs 0.000 claims description 28
- 229960000701 fenofibric acid Drugs 0.000 claims description 26
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 claims description 26
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 26
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 23
- 238000011200 topical administration Methods 0.000 claims description 22
- 208000030533 eye disease Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000003889 eye drop Substances 0.000 claims description 16
- 229960005150 glycerol Drugs 0.000 claims description 14
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 11
- 208000022873 Ocular disease Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229940068965 polysorbates Drugs 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 6
- 208000002691 Choroiditis Diseases 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 5
- 201000010183 Papilledema Diseases 0.000 claims description 5
- 208000003971 Posterior uveitis Diseases 0.000 claims description 5
- 206010038886 Retinal oedema Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 201000010230 macular retinal edema Diseases 0.000 claims description 5
- 201000011195 retinal edema Diseases 0.000 claims description 5
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 4
- WEBILLRFBZTUIX-BTJKTKAUSA-N 2-(1-adamantyl)ethyl 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetate;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)CC(C3)CC2CC3C1 WEBILLRFBZTUIX-BTJKTKAUSA-N 0.000 claims description 4
- 229930105110 Cyclosporin A Natural products 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 4
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- -1 immunoregulator Substances 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229960002509 miconazole Drugs 0.000 claims description 4
- 229960001416 pilocarpine Drugs 0.000 claims description 4
- 229960002702 piroxicam Drugs 0.000 claims description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 229940118169 Prostaglandin receptor agonist Drugs 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000000472 muscarinic agonist Substances 0.000 claims description 2
- 239000004090 neuroprotective agent Substances 0.000 claims description 2
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims description 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims 1
- 206010027646 Miosis Diseases 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000003547 miosis Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 44
- 210000001508 eye Anatomy 0.000 description 40
- 239000007908 nanoemulsion Substances 0.000 description 25
- 239000001087 glyceryl triacetate Substances 0.000 description 13
- 229960002622 triacetin Drugs 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 210000001525 retina Anatomy 0.000 description 10
- 210000001742 aqueous humor Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229940075495 isopropyl palmitate Drugs 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 229940012356 eye drops Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- RROLKYCVTJGMND-UHFFFAOYSA-N 1-acetyl-5-hydroxyanthracene-9,10-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C=CC=C2C(=O)C RROLKYCVTJGMND-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000000695 crystalline len Anatomy 0.000 description 5
- 229940074928 isopropyl myristate Drugs 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010587 phase diagram Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 108700028490 CAP protocol 2 Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 208000029515 lens disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784005P | 2013-03-14 | 2013-03-14 | |
| US61/784,005 | 2013-03-14 | ||
| PCT/US2014/025773 WO2014160079A1 (en) | 2013-03-14 | 2014-03-13 | Microemulsion topical delivery platform |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512562A JP2016512562A (ja) | 2016-04-28 |
| JP2016512562A5 true JP2016512562A5 (https=) | 2017-02-23 |
| JP6348567B2 JP6348567B2 (ja) | 2018-06-27 |
Family
ID=50628949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501962A Active JP6348567B2 (ja) | 2013-03-14 | 2014-03-13 | マイクロエマルジョン局所送達プラットフォーム |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8968775B2 (https=) |
| EP (1) | EP2968139B1 (https=) |
| JP (1) | JP6348567B2 (https=) |
| CN (1) | CN105451718B (https=) |
| AU (1) | AU2014244154B2 (https=) |
| CA (1) | CA2905023C (https=) |
| DK (1) | DK2968139T3 (https=) |
| ES (1) | ES2673009T3 (https=) |
| PL (1) | PL2968139T3 (https=) |
| PT (1) | PT2968139T (https=) |
| TR (1) | TR201808197T4 (https=) |
| WO (1) | WO2014160079A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2041156E (pt) | 2006-07-13 | 2014-02-21 | Achillion Pharmaceuticals Inc | Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| AU2017208970A1 (en) | 2016-01-18 | 2018-08-02 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| EP3266446B1 (en) * | 2016-07-07 | 2018-11-21 | Laboratorios SALVAT, S.A. | Ophthalmic composition comprising castor oil and medium chain triglyceride |
| WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
| WO2019045994A1 (en) * | 2017-08-27 | 2019-03-07 | Rhodes Technologies | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS |
| US11583497B2 (en) | 2017-11-14 | 2023-02-21 | The Schepens Eye Research Institute, Inc. | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery |
| EP3982930A1 (en) | 2019-06-11 | 2022-04-20 | SIFI S.p.A. | Microemulsion compositions |
| CN117660024A (zh) * | 2019-07-08 | 2024-03-08 | 株式会社Moresco | 微型乳剂、用于制造微型乳剂的方法以及微型乳剂的用途 |
| WO2022107886A1 (ja) * | 2020-11-19 | 2022-05-27 | 学校法人日本大学 | 網膜循環障害及び網膜神経血管連関障害の改善用又は予防用点眼剤 |
| WO2023053077A1 (en) * | 2021-10-01 | 2023-04-06 | University Of South Africa | A nano emulsified phyto-drug for transdermal treatment of diabetes |
| AU2024322403A1 (en) * | 2023-08-04 | 2026-02-12 | Ads Therapeutics Llc | Compositions and methods for delivery of ophthalmological actives |
| WO2025090133A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI398261B (zh) * | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
| US7915247B1 (en) * | 2006-08-21 | 2011-03-29 | Mutual Pharmaceutical Company, Inc. | Methods of use of fenofibric acid |
| US20090082470A1 (en) * | 2007-09-24 | 2009-03-26 | Rafal Farjo | Stat3 inhibiting compositions and methods |
| US8652443B2 (en) * | 2008-02-14 | 2014-02-18 | Precision Dermatology, Inc. | Foamable microemulsion compositions for topical administration |
| CN103402582A (zh) * | 2011-02-11 | 2013-11-20 | 普西维达公司 | 使用抗水肿疗法治疗黄斑水肿的方法 |
| WO2013049621A1 (en) * | 2011-09-29 | 2013-04-04 | The Board Of Regents Of The University Of Oklahoma | Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof |
-
2014
- 2014-03-13 PT PT147207864T patent/PT2968139T/pt unknown
- 2014-03-13 DK DK14720786.4T patent/DK2968139T3/en active
- 2014-03-13 ES ES14720786.4T patent/ES2673009T3/es active Active
- 2014-03-13 CN CN201480027477.7A patent/CN105451718B/zh active Active
- 2014-03-13 AU AU2014244154A patent/AU2014244154B2/en active Active
- 2014-03-13 EP EP14720786.4A patent/EP2968139B1/en active Active
- 2014-03-13 TR TR2018/08197T patent/TR201808197T4/tr unknown
- 2014-03-13 CA CA2905023A patent/CA2905023C/en active Active
- 2014-03-13 JP JP2016501962A patent/JP6348567B2/ja active Active
- 2014-03-13 WO PCT/US2014/025773 patent/WO2014160079A1/en not_active Ceased
- 2014-03-13 PL PL14720786T patent/PL2968139T3/pl unknown
- 2014-03-14 US US14/212,675 patent/US8968775B2/en active Active - Reinstated
-
2015
- 2015-02-24 US US14/630,073 patent/US9149453B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6348567B2 (ja) | マイクロエマルジョン局所送達プラットフォーム | |
| JP2016512562A5 (https=) | ||
| JP7496778B2 (ja) | チモロールを含む医薬組成物 | |
| JP7547411B2 (ja) | 局所用シクロスポリン含有製剤およびその使用 | |
| JP7353292B2 (ja) | ネビボロールを含む医薬組成物 | |
| JP5441058B2 (ja) | 四級アンモニウム化合物を含む組成物 | |
| US20210085603A1 (en) | Microemulsion for opthalmic drug delivery | |
| KR101587412B1 (ko) | 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물 | |
| JP7669326B2 (ja) | 局所製剤およびその使用 | |
| JP2017519813A (ja) | 局所製剤およびその使用 | |
| JP2018532809A5 (https=) | ||
| KR20150000405A (ko) | 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법 | |
| CN116898800A (zh) | 无防腐剂的眼科药物乳剂及其应用 | |
| KR101151235B1 (ko) | 나노에멀젼 형태의 안과용 조성물 | |
| US20140302099A1 (en) | Ophthalmic Composition Containing Cyclosporine And method For Preparing Same | |
| Acharya | Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents | |
| HK40044057A (en) | Pharmaceutical compositions comprising nebivolol | |
| HK40044057B (zh) | 包含奈必洛尔的药物组合物 |